Atenolol-AFT Update

We currently have a stock shortage of Atenolol-AFT (atenolol 50 mg/10 mL) oral liquid 300 mL in both Australia and New Zealand. The only product currently held by AFT Pharmaceuticals expires in October 2018.

Due to problems at the manufacturing site we do not expect new stock to be available until February 2019. We are working with the manufacturer to expedite production of new stock.

We apologise for any inconvenience that is caused by this out of stock situation but it is due to circumstances outside of our control.

July 23, 2026

Pitt St Research initiates coverage on AFT Pharmaceuticals

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that Pitt St Research has initiated coverage on AFT Pharmaceuticals Ltd….

Read More

May 21, 2026

AFT delivers double digit revenue growth and record earnings

Operating profit or $24.4 million ahead of the guidance range….

Read More

May 18, 2026

AFT Pharmaceuticals names Stuart Houliston CFO

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company, today advises that Stuart Houliston will commence …

Read More